


2022
Advancing
HIV, STI and
Viral
Hepatitis
Testing
Conference



Tuesday, March, 29, 2022

10:00 am –11:30 am		A1: Educational Session	
	10:00 am –10:15 am	ES1. Impacts of the COVID-19 Pandemic on Advancing HIV, STI and Viral Hepatitis Testing	Megan Crumpler
	10:15 am – 10:30 am	ES2. Overview of HIV Testing Practices and Technology	Michele S. Owen
	10:30 am – 10:45 am	ES3. STI Testing Technology	Barbara Van der Pol
	10:45 am – 11:00 am	ES4. Hepatitis C Virus Test Technology	Saleem Kamili
	11:00 am – 11:15 am	ES5. Debrief of the HCV Diagnostics Conference	Carolyn Wester
	11:15 am – 11:30 am	Moderated Q & A	
12:00 pm – 1:00 pm		A2: Opening Session: Testing as a Gateway to Prevention and Care	
	Welcome		Rochelle Walensky
	Panel	Moderator:	Jonathan Mermin
		Panelists:	Demetre Daskalakis
			Leandro Mena
			Carolyn Wester
1:30 PM - 2:00 PM		Live Chat Poster Session A	
		PA1. Evaluation of the Abbott Alinity m STI assay for diagnosis of the primary causes of sexually transmitted infections in the United States	James E. Kirby
		PA2. Performance of Self-collected Penile-meatal Swabs Compared to Urine for Detection of STIs in a Low Resource Setting with High Prevalence of STIs	Johan H. Melendez
		PA3. Evaluation of the Alinity m STI Assay at a Veterans Administration Hospital	Robert J. Rolfe
		PA4. Real-World HIV Diagnostic Testing in the United States: Assessing the 2nd Step of the Algorithm	Sara Blosser
		PA5. Implementation of HCV RNA testing at a Local Public Health Laboratory	Mariam Zhouwandai
2:00 PM - 3:45 PM		A3 Session 1: Nucleic Acid Tests	
	2:00 PM - 2:15 PM	1A. A Shared Service Model for HIV Nucleic Acid Testing and the Impact of COVID-19	Lauren Johnson

	2:15 PM - 2:30 PM	1B. Multisite Evaluation of an HIV-1 panel on the Alinity m HIV-1 assay and its relevance to critical clinical decision points	Whitnie Crown
	2:30 PM - 2:45 PM	1C. HIV/HCV Screening, Testing, and Diagnostic Reliability during the Acute Encounter with the Cepheid GeneXpert	Jason Wilson
	2:45 PM - 3:00 PM	1D. Evaluation of the Aptima HCV Quant Dx Assay for qualitative and quantitative RNA detection in Dried Blood Spots	Renee Hallack
	3:00 PM - 3:15 PM	1E. Validation of new STI panel for Abbott Alinity m	Karen C. Rexroth
	3:15 PM - 3:30 PM	1F. The Clinical and Cost Implications of Using HIV RNA Instead of Antibody Testing to Confirm Reactive HIV Screening Tests in the United States	Daniel Gromer
	3:30 PM - 3:45 PM	Live Moderated Q&A	Moderator: Jeffery A. Johnson

4:00 PM - 5:00 PM	A4 Discussion Panel: Using a molecular test as the second test in the HIV diagnostic algorithm		
	Discussants:		Bernard Branson
			Monica Parker
			S. Berry Bennett
			Joseph Yao
			Jeffery A. Johnson
	Moderator:		S. Michele Owen

Wednesday, March 30, 2022

10:00 am -11:00 am	B1 Discussion Panel 2: The utility of multiplex versus singleplex or lower plex testing in STI diagnostics		
	Discussants:		James Kirby
			Kevin Ard
			Erica Hardy
			Christina Muzny
			Katherine Hsu
	Moderator:		Barbara Van Der Pol

11:15 AM - 12:15 PM	B2 Session 2: Recently Marketed Tests		
	11:15 am – 11:30 am	2A. Evaluation of the DPP HIV-Syphilis test performance characteristics at the point-of-care clinical setting (FDOH-Miami-Dade STD clinical lab). "	Olga V. Ponomareva
	11:30 am- 11:45 am	2B. Performance of the Avioq VioOne HIV Profile Supplemental Assay for Confirmation and Differentiation of HIV-1 and HIV-2 Antibodies at a State Public Health Laboratory. "	S. Berry Bennett
	11:45 am – 12:00 pm	2C. Visby Medical Sexual Health Click test: A patient-centric approach to diagnosing sexually transmitted infections "	Teresa M. Abraham
	12:00 pm - 12:15 pm	Live Moderated Q&A	Moderator: Ellen Kersh

1:15 PM - 1:45 PM	Live Chat Poster Session B		
		PB1. Hepatitis C Testing during a Global Pandemic: San Francisco's Lessons Learned	Shelley N. Facente
		PB2. Factors Associated with Accepting HIV tests in the United States: A Systematic Review f Nebraska Medical Center	Titilola Labisi

		PB3. Patient Flow Assessed in Preparation for Point-of-care HIV Nucleic Acid Testing (POC NAT) Implementation at a Large HIV Clinic in Seattle, Washington "	Lisa A Niemann
		PB4. Analyzing Trends in HSV Western Blot Results at a Reference Laboratory "	Abir Hussein
		PB5. False Positive Results on HSV 2 Confirmatory Test Used at Major US Laboratory Compared to Gold Standard Herpes Western Blot "	Terri Warren
1:45 pm – 3:15 pm	B3 Session 3: Optimizing Testing Opportunities		
	1:45 pm - 2:00 pm	"3A. Testing 1-2-3: A Novel Approach to STI/HIV testing in Rhode Island "	Siena Napoleon
	2:00 pm – 2:15 pm	"3B. CDC's Direct-to-consumer Distribution of 100,000 HIV self-tests "	Pollyanna R. Chavez
	2:15 pm – 2:30 pm	"3C. Infectious Disease Testing at a Syringe Services Program (SSP) "	Heather Henderson
	2:30 pm – 2:45 pm	"3D. Promoting HIV and Hepatitis C Virus Testing and Linkage to Harm Reduction Resources Through Navigation Programs "	Shamia Roberts
	2:45 pm – 3:00 pm	"3E. Optimizing Hepatitis C Virus Screening using Automation in an Urban Emergency Department "	Melisa Hart
			Minh Tran
	3:15 pm – 3:30 pm	Moderated Q&A	Moderator: Jenny R. McFarlane
3:30 pm – 4:30 pm	B4 Discussion Panel 3 :The Reddit Community asks the experts about STIs. Here's what we discovered...		
		Discussants:	Barbara Van Der Pol
			Srishti Baid
			Miguel Quinones-Mateu
		Moderator:	Megan Crumpler
Thursday, March 31, 2022			
10:00 am –11:30 am	C1: Session 4: Testing Challenges		
	10:00 am – 10:15 am	"4A. Biotin Interference in Point of Care HIV Immunoassay "	Mohan Kumar Haleyur Giri Setty
	10:15 am – 10:30 am	"4B. Equivocal HIV Screening Results in the Emergency Department. False Positive or Acute Seroconversion? "	Jason Wilson
	10:30am – 10:45 am	"4C. Longitudinal Specificity of the BioPlex 2200 HIV Ag-Ab Combination Assay in Routine Screening in a US Public Health Laboratory "	Alfredo Villarreal
	10:45am – 11:00 am	"4D. Do COVID antibodies cross-react with the BioPlex 2200 HIV Ag-Ab differentiating combination screening assay? "	Payu A. Raval
	11:00 am – 11:15 am	"4E. Seroconversion, seroreversion, and serowaffling among participants in Project DETECT "	Joanne Stekler
	11:15 am – 11:30 am	Moderated Q&A	Moderator: Richard L. Hodinka
11:45 am – 12:45 pm	C2 Discussion Panel 4 Opportunities and challenges with using HIV recency testing and other metrics to monitor progress towards Ending the HIV Epidemic		
		Discussants	Shelley Facente
			Kate Mitchell
			Chris Beyrer

		Moderator	Kevin Delaney
1:15 pm – 1:45 pm	Live Chat Poster Session C		
		PC1. A comparison of clinical characteristics of neurosyphilis between HIV infected and non-HIV patients at Maharat Nakhon Ratchasima Hospital	Chalothorn Wannaphut,
		PC2. Challenges of PrEP Regimen Adherence and Monitoring of Kidney Function on Self-collect DBS	Kavinda DeSilva
		PC3. Emergence of Syphilis Infection beyond HIV Infection as a more Relevant Indicator for Hepatitis C Virus Infection Susceptibility	Cynthia Turner
		PC4. Self-collect diagnostic options facilitate PrEP engagement and persistence	Christopher S. Hall
1:45 pm – 3:00 pm	C3: Session 5: Emerging Technology		
	1:45 pm – 2:00 pm	"5A. Development of a serologic assay for differentiating acute from chronic HCV infection "	Matthew Pauly
	2:00 pm – 2:15 pm	"5B. A laboratory-developed quantitative hepatitis B surface antigen (qHBsAg) test detects 8 major HBV genotypes and sG145R mutants "	Mary Lape Nixon
	2:15 pm – 2:30 pm	"5C. Time to leave Fiebig staging in the dust? Estimated Dates of Detectable Infection (EDDIs) as a new and improved method for HIV infection dating "	Shelley Facente
	2:30 pm – 2:45 pm	"5D. Use of the Geenius Index to indicate recent HIV infection in Project DETECT "	Lauren Violette
	3:00 pm – 3:15 pm	Live Moderated Q&A	Moderator: Kelly Curtis
3:15 pm – 4:15 pm	C4: Discussion Panel 5 : Detecting and confirming acute or incident HIV infection in persons taking antiretrovirals for PrEP		
	3:15 PM - 4:15 PM	Discussants:	Adam Visconti
			Raphael Landovitz
			Susan Eshleman
			Moderator: Dawn Smith
Friday, April 1, 2022			
10:00 am –11:00 am	D1: Feedback Session: Regulatory Issues Related to Self-collection and Remote Testing (led by FDA and CDC)		
		Panelists:	Julia Lathrop
			S. Michele Owen
			Ellen Kersh
			Timothy Stenzel
11:15 am – 12:45 pm	D2: Session 6: Mail-in Testing		
	11:15 am – 11:30 am	"6A. Addition of Extragenital STI testing in "I Want The Kit" Program Users "	Tong Yu
	11:30 am – 11:45 am	6B. I Want The Kit (IWTK): Improving an online platform for STI specimen at-home self-collection and laboratory testing	Gretchen Armington
	11:45 am – 12:00 pm	6C. Preparing for a Home-Based Self-Sampling STI/HIV Testing Pilot Program	Ashton Morris
			Johnnie Green

	12:00 pm – 12:15 pm	6D. GetCheckedDC: A Mail-in STI Testing Pilot Program	Kenya Troutman
	12:15 pm – 12:30 pm	6E. Implementing a novel home HIV/STI testing program	Jennifer Hecht
	12:30 pm – 12:45 pm	Moderated Q&A	Moderator: Liisa Randall
1:15 pm – 1:45 pm	Live Chat Poster Session D		
		PD1. Automated Sexual History and Self-Collection of Chlamydia and Gonorrhea Specimens Improves Diagnoses	Kelly S. Chapman
		PD2. STI sampling at home: Telemedicine usage and high negative predictive values of self-collection STI screening	Daniel Kreitzberg
		PD3. A review of the scope of direct-to-consumer sexually transmitted infection testing services offered on the internet	Casey N. Pinto
		PD4. Bacterial Sexually Transmitted Infection Testing and Treating Barriers	John A. Nelson
2:00 pm – 4:00 pm	D3: Session 7: Self-collected Micro-sampling		
	2:00 pm – 2:15 pm	7A. Actionable multi-targeted STI testing using self-collect DBS for high-risk populations	Zoe Goedecke
	2:15 pm – 2:30 pm	7B. Validation and prospective evaluation of mailed dried blood spot (DBS) for dual detection of HIV and syphilis using the DPP® HIV-Syphilis test	Johan H. Melendez
	2:30 pm – 2:45 pm	7C. Clinical Utility of Hepatitis C Viral Load Detected via Dried Blood Spot Card At-Home Collection	Mariko Nakano
	2:45 pm – 3:00 pm	7D. The implementation of self-collected Microtainer™ specimens in a large research project—iSTAMP	Amanda J. Smith
	3:00 pm – 3:15 pm	7E. Self-collected Microtainer™ specimens for HIV viral load testing: a step towards HIV telemedicine	Jeffrey A. Johnson
	3:15 pm – 3:30 pm	7F. Evaluation of self-collected Microtainer™ specimens for measuring antiretroviral drugs	Richard E. Haaland
	3:30 pm – 4:00 pm	Moderated Discussion on Self-collected Micro-sampling	Moderator: Joanne Mei
4:15 PM - 4:45 PM	Closing Statements	S. Michele Owen	